By Greenyn Biotechnology Co., Ltd.

TAIPEI and TAICHUNG, Aug. 27, 2024 /PRNewswire/ — Modern lifestyle is often associated with irregular routines, high-fat/high-salt diets and refined foods as well as less physical activities, which increase the incidence and prevalence of the diseases of civilization.

Metabolic syndrome encompasses issues like abnormal blood lipids, blood sugar, and abdominal obesity (central obesity). Insulin resistance is the primary cause of metabolic syndrome. Prolonged poor blood sugar control can easily lead to diabetes and even other chronic diseases. According to statistics from Ministry of Health, Labour and Welfare, the number of diabetes patients in Japan has exceeded 10 million, with an increasing trend as the population ages. Driven by this substantial demand, bitter melon extract emerged, leading to their popularity in the market.

Potential Plant Insulin

Bitter melon (Momordica charantia Linn.), a member of the Cucurbitaceae family, is a traditional Chinese herbal medicine. Many studies have confirmed that bitter melon contains various blood sugar-lowering components, primarily including terpenes, phytosterols, and peptides. There are many related products on the market extracted from bitter melon (see Table 1). The mechanisms of action range from improving insulin sensitivity, inhibiting glucose-degrading enzymes, to directly binding with insulin receptors(3). With various blood sugar regulation mechanisms, bitter melon has gained significant attention in the field of blood sugar control. However, research shows that if specific component structures are not extracted or if the product is only following market trends and not adequately utilized, over time, ineffective feedback from consumers may lead to market saturation, causing high-quality products to be overlooked.

Research on Commercial Bitter Melon Health Ingredients

Research on Patented Amino Peptide Sequence mcIRBP-19

In an environment saturated with products claiming to contain bitter melon peptides, many of these lack scientific validation of their functionality or physiological mechanisms. The market is chaotic, with products of varying quality. Due to the complex mechanism of blood sugar regulation, there is rarely a substance that can substitute for insulin in regulating blood sugar. Greenyn Biotechnology has conducted in-depth research on bitter melon, focusing on the essential nature of the plant. They have verified that the specific amino peptide sequence mcIRBP-19, consisting of 19 amino acids, is a rare natural substance that can directly bind to the diabetes-causing target – the insulin receptor. They completed structural sequencing and quantitative analysis, providing scientific evidence that repeatedly confirms its unique physiological function. Additionally, they have conducted several in vivo studies, which are detailed as follows:

Regulating Blood Sugar and Assisting in the Treatment of Diabetes

Diabetes is a hard to cure, and its alarming annual increase rate of 25,000 cases is not the only cause for concern. The complications it leads to, such as retinopathy, neuropathy, and cardiovascular diseases, are even more significant.

Through animal experiments analyzing fasting blood sugar and post-meal blood sugar regulation capabilities, it was found that the patented amino peptide sequence 19 (mcIRBP-19) can reduce fasting blood sugar by 50% and glycosylated hemoglobin by 38%. Additionally, it maintains a balanced insulin level in the body. Furthermore, it prevents a significant increase in post-meal blood sugar, rapidly regulating blood sugar within 2 hours. Its exceptional ability to stabilize blood sugar can significantly reduce the occurrence of complications caused by diabetes, such as retinopathy.

Human clinical studies have shown (4) that the patented amino peptide sequence 19 (mcIRBP-19) can assist in significantly reducing fasting blood sugar and glycosylated hemoglobin within 12 weeks for individuals who have shown insufficient improvement with conventional diabetes medication. It can also effectively improve the quality of life for patients (5). For sub-healthy individuals with diabetes, mcIRBP-19 can help regulate fasting blood sugar, stabilize glycated hemoglobin, and prevent the onset of diabetes. These clinical trials have verified the potential efficacy of this ingredient

Reducing Body Fat, Blood Lipids, and Anti-Inflammation

In addition to unstable blood sugar, metabolic syndrome also involves issues with abnormal blood lipids, central obesity, and chronic inflammation. Animal experiments (6) have shown that the patented amino peptide sequence 19 (mcIRBP-19) can regulate fatty acid metabolism and genes related to fatty liver. It effectively reduces body fat percentage by 25.5%, significantly decreasing white fat in the liver. This helps prevent the occurrence of fatty liver and avoids liver damage. Furthermore, chronic inflammation, much like an internal fire, can lead to various diseases, including cancer. The patented sequence 19 peptide can effectively reduce the expression of inflammatory factors in various organs, thus preventing the onset of chronic diseases.

Conclusion

The human body is like a machine. When metabolic syndrome occurs, it’s like screws gradually loosening. Continued operation can easily lead to machine failure, resulting in conditions such as chronic diseases and cancer. At such times, we urgently need a helper who can tighten the screws.

The structure of mcIRBP-19, with the potential of a plant-derived insulin, is extracted using patented technology. The functional 19 amino acids are fully sequenced. Through a series of animal and clinical experiments, it has been confirmed to stabilize both pre-meal and post-meal blood sugar levels, reduce body fat and blood lipids, and achieve anti-inflammatory effects while providing adjunctive treatment for diabetes. This not only brings a ray of hope to diabetes patients, preventing the deterioration of their condition, but also takes into account their quality of life. It offers everyone a safe and effective natural preventive health option for daily life.

Reference
1. Wang HY, et al. Food Chem Toxicol. (2014) 69:347-356.
2. Dallas LC, et al. J Med Food. (2011) 14:1496-1504.
3. Lo HY, et al. J Agric Food Chem. (2013) 61:2461-2468.
4. Hsu PK, et al. Nutrients (2020) 12:1252.
5. Pan F, et al. Risk Manag Healthc Policy. (2020) 13:2219-2226.
6. Patent Invention No. I580690, Republic of China.

LINE TODAY:https://today.line.me/hk/v2/article/vX6yBX8

25-Feb-2022 By Liza Laws

Bitter melon peptides significantly reduce blood sugar levels in patients who had previously failed to respond to their medications, a study has found.

Source from:

https://www.nutraingredients-usa.com/Article/2022/02/25/bitter-melon-an-alternative-diabetic-medicine-study-says#

Taiwan’s biotech is gradually emerging. During the COVID-19 epidemic, we had a chance to see the advanced medical equipment and the effective preventive measures taken at the community level. The government took precautions, while private companies were introducing high-quality biotechnology products made in Taiwan. In the post-pandemic period, the world may become more sensitive to the need to strengthen prevention and improve medical treatment. The Taiwan Greenyn Group has been developing health foods for the global market for over 20 years. On Sept. 8, Greenyn Biotechnology, a member of the Greenyn Group, presented clinical results for Insumate®–Patented Peptide Sequence: mcIRBP-19.

Taiwan Greenyn Group: Chairman Wu Chia-feng (middle), CEO Luo Husan (left), and Dr. Hsu Pang-kuei (right), displaying certificates of research results.

Mr. Wu Chia Feng, Chairman of Taiwan Greenyn Group, pointed out, “Greenyn Biotechnology was established in 2012 as a subsidiary of Taiwan Greenyn Corporation. The company has many experts in medical and food biotechnology. Greenyn Biotechnology has invested heavily in research and development over the years, and finally, their products are receiving international recognition. The main goal of the company is to improve the quality of life for all people through preventive medicine.”

Among chronic diseases, the health problems caused by diabetes are particularly pervasive, and growing at an alarming rate. According to data released by the International Diabetes Federation, 463 million people were living with diabetes at the end of 2019, with related medical expenses of US$760 billion. Each year, 4.2 million people die from diabetes and its complications. With insufficient action, these numbers will continue to spiral. China, Southeast Asia, and the Western Pacific Region account for 35% of all diabetics, one third of all confirmed cases.

Dr. Yang Yi-tien (middle) of Chung Shan Medical University Hospital, which has a collaboration with Greenyn Biotechnology Corporation, displays outstanding results of randomized double-blind clinical trials.

As the company was being established nearly10 years earlier, researchers were already conducting trials on animal and human cells, and discovering that mcIRBP-19 had the potential to regulate blood sugar. Greenyn Biotechnology partnered with Chung Shan Medical University Hospital to conduct clinical trials on diabeties and functional food therapies. Professional medical teams worked tirelessly to carry out these trials, which finally obtained double approval from the Institutional Review Board (IRB). Greenyn Biotechnology confirmed on a scientific basis that a highly active extract from bitter gourd correlated with human insulin receptors. Greenyn Biotechnology called the extract “Patented Peptide Sequence: mcIRBP-19”, and the brand, “Insumate®.”

Dr. Yang Yi-Tien of Chung Shan Medical University Hospital conducted the randomized double-blind clinical trial, which confirmed that Patented Peptide Sequence: mcIRBP-19 had outstanding results on diabetic patients who undertook adjuvant therapy. The trial was conducted on 29 diabetics who were long-term patients of hypoglycemic drugs of less effectiveness. Without breaking routine drug therapy, the diabetic trials were conducted for 3 months, concluding that fasting blood sugar and glycosylated hemoglobin in the therapy group were significantly reduced. Their liver function, kidney function, and hemoglobin remained unchanged. There were no side effects of hypoglycemia and allergic gastrointestinal discomfort, which usually occur to users of oral hypoglycemic drugs. As for the control group, there was no noticeable difference. The clinical results are being submitted to an International Journal.

Taiwan Greenyn Group No.2 Factory

The unique structure of Patented Peptide Sequence: mcIRBP-19 allows for use as a pathogenic target. These results have been published in the Science Citation Index (SCI). Dr. Hsu Pang-kuei, chief of research and development at Greenyn Biotechnology, has been conducting research for more than a decade. “After many years, we discovered that mcIRBP-19 has a hypoglycemic effect on insulin-like biological activities and can bind insulin receptors. Without stimulating insulin secretion, mcIRBP-19 can participate in the body’s carbohydrate metabolism and regulate blood sugar. Besides insulin, mcIRBP-19 has been scientifically confirmed as a natural product able to bind insulin receptors to regulate blood sugar.” said Dr. Hsu. Yet another clinical trial reported that 142 diabetics who were long-term users for hypoglycemic drugs took mcIRBP-19 for 3 months, and their blood sugar indexes and glycosylated hemoglobin were well regulated. These results were published in the world-famous Journal of Nutrition.

Insumate®: mcIRBP-19 functions to regulate blood sugar, processing at low temperatures with high activity, and passing toxicity tests. This biotechnology innovation has helped Greenyn Biotechnology in obtaining 19 patent certificates and recognition from the world’s largest discovery exhibitions, the Discovery and New Products Expo (INPEX) in Pittsburgh, Pa, USA; International Discovery Exhibition of Geneva, Switzerland; and the Nuremberg International Expo (IENA) in Germany. An extensive summary of mcIRBP-19 has also been published in the Scientific Citation Index (SCI). Presently, many well-known international process manufacturers use ingredients provided by Greenyn Biotechnology to produce health foods. Greenyn Biotechnology attributes these achievements to its utmost efforts in recent years.

Insumate® –Patented Peptide Sequence: mcIRBP-19, a naturally extracted product.

As Dr. Hsu pointed out, “There are many similar products on the market, called bitter melon peptide or peptide-related peptide. But under professional tests, they are only hydrolyzed water or bitter watermelon extract. They do not contain any ingredients able to regulate blood sugar as Insumate®: mcIRBP-19. The most important thing is that strictly selected ingredients must be certified and scientifically validated locally and internationally. Only after rigorous quality testing can the product achieve its medical purpose.”

Mr. Yang Lihua, Secretary General of the Taiwan Functional Food Industry Association, said, “The Taiwan Greenyn philosophy is to rigorously pursue innovative R&D in precision medicine. We define precision medicine as a combination of prevention, healthcare, and clinical testing. Even with the support of scientific testing, improving medicine into a method of prevention takes a long time. With incredible investment and perseverance, Taiwan Greenyn has become a model for various Taiwanese industries due to continuous innovation. They have improved Taiwanese medicine into precision medicine.”

To ensure excellent product quality, Greenwyn Biotechnology has developed a comprehensive, one-stop service solution in areas such as product development, market positioning, formula design, packaging design, manufacturing design, clinical planning, marketing planning and customer service. Greenyn is dedicated to creating new futures for tomorrow’s healthy lifestyles.

Among chronic diseases, the health problems caused by diabetes are particularly pervasive, and growing at an alarming rate. According to data released by the International Diabetes Federation, 463 million people were living with diabetes at the end of 2019, with related medical expenses of US$760 billion. Each year, 4.2 million people die from diabetes and its complications. With insufficient action, these numbers will continue to spiral. China, Southeast Asia, and the Western Pacific Region account for 35% of all diabetics, one third of all confirmed cases.

Dr. Yang Yi-Tien of Chung Shan Medical University Hospital conducted the randomized double-blind clinical trial, which confirmed that Patented Peptide Sequence: mcIRBPTM-19 had outstanding results on diabetic patients who undertook adjuvant therapy. The trial was conducted on 29 diabetics who were long-term patients of hypoglycemic drugs of less effectiveness. Without breaking routine drug therapy, the diabetic trials were conducted for 3 months, concluding that fasting blood sugar and glycosylated hemoglobin in the therapy group were significantly reduced. Their liver function, kidney function, and hemoglobin remained unchanged. There were no side effects of hypoglycemia and allergic gastrointestinal discomfort, which usually occur to users of oral hypoglycemic drugs. As for the control group, there was no noticeable difference. The clinical results are being submitted to an International Journal.

The unique structure of Patented Peptide Sequence: mcIRBP^TM-19 allows for use as a pathogenic target. These results have been published in the Science Citation Index (SCI) journals. Dr. Hsu Pang-kuei, chief of research and development at Greenyn Biotechnology, has been conducting research for more than a decade. “After many years, we discovered that mcIRBP^TM -19 has a hypoglycemic effect on insulin-like biological activities and can bind insulin receptors. Without stimulating insulin secretion, mcIRBP^TM-19 can participate in the body’s carbohydrate metabolism and regulate blood sugar. Besides insulin, mcIRBP^TM-19 has been scientifically confirmed as a natural product able to bind insulin receptors to regulate blood sugar,” said Dr. Hsu. Yet another clinical trial reported that 142 diabetics who were long-term users for hypoglycemic drugs took mcIRBP^TM -19 for 3 months, and their blood sugar indexes and glycosylated hemoglobin were well regulated. These results were published in the world-famous Journal of Nutrition.

Insumate^®: mcIRBP^TM-19 functions to regulate blood sugar, processing at low temperatures with high activity, and passing toxicity tests. This biotechnology innovation has helped Greenyn Biotechnology in obtaining 19 patent certificates and recognition from the world’s largest discovery exhibitions, the Discovery and New Products Expo (INPEX) in Pittsburgh, Pa, USA; International Discovery Exhibition of Geneva, Switzerland; and the Nuremberg International Expo (IENA) in Germany. An extensive summary of mcIRBP^TM-19 has also been published in the Scientific Citation Index (SCI) journal. Presently, many well-known international process manufacturers use ingredients provided by Greenyn Biotechnology to produce health foods. Greenyn Biotechnology attributes these achievements to its utmost efforts in recent years.

Article: Hsu Wen-Yuan

The potential of bitter melon peptides to regulate glucose has attracted the attention of many diabetics, but is there scientific evidence that it can help in stabilizing blood glucose? Commercially available products include a wide range, how does one choose?
According to statistics, Taiwan has 2 million confirmed diabetics. This number is increasing at a rate of approximately 30,000 per year with over 90% being type-II diabetes; furthermore, the age of patients continues to lower. The modern lifestyle of refined diets and low activity has caused obesity to be a major challenge in global health issues. According to an investigation by the Health Promotion Administration, the rate of overweight and obese adults in Taiwan is 45.4%; obesity is a key risk factor in type-II diabetes.
Currently, there are no true treatments for diabetes. Patients must control the disease through medication and assertively control their diets in combination with exercise and weight loss. However, many patients cannot sustain this and sometimes give up on regulating blood glucose which can lead to serious complications as time passes.
Over the recent years, the trend has been to use natural therapies to assist with regulating blood glucose. The main pathogenic target of diabetes are insulin receptors which is why many continue to search for natural substances that can substitute for insulin in insulin receptors. This has proved challenging due to the complications of physiological mechanisms but many so-called plant insulin products that have no scientific evidence to back them have confused consumers.
Thus, Taiwanese companies partnered with medical universities and spent a decade researching to finally discover an active ingredient with high affinity with human insulin receptors from bitter melons – “Patented peptide sequence”. The substance is called “mcIRBP^TM-19″ internationally and there have been 4 scientific studies published in international journals since 2013. The studies have been performed and verified in clinical trials using cells, animals, and humans.
Research on the Effects of Patented peptide sequence on Glucose Regulation
The body′s glucose transporting mechanism must be activated so that glucose in the blood is transported into cells or risk causing high blood glucose. Biochemical expert Hsu Pang-Kuei, PhD states that Patented peptide sequence (mcIRBP^TM-19) extracted from bitter melons is the only scientifically proven natural substance that can combine with insulin receptors aside from insulin and can maintain stable blood glucose; in order to further verify its effects, 142 diabetes patients with chronic prescriptions and blood glucose between 120~140 who did not show improvement from medication were selected. Their medication remained unchanged, but blood tests after 3 months found that using Patented peptide sequence (mcIRBP^TM-19) as a supplement in the experiment group not only decreased fasting blood glucose, there was also significant improvement in glycosylated hemoglobin.
Glycosylated hemoglobin can reflect the average blood glucose concentration during the survival period (average of 3 months) of erythrocyte; “patients who normally pay no attention to their diet may have low blood glucose values in the outpatient clinic, but exhibit increased glycosylated hemoglobin meaning their blood glucose regulation has been unstable over the past 3 months.” Hsu Pang-Kuei, PhD emphasizes that when glycosylated hemoglobin is high, one must consider intervention with a suitable amount of sport activity or supplement measures.
The above report was published during 2020 in the international journal <Nutrients>. Additionally, a double-blind test for patients with blood glucose levels between 160~180 was conducted in partnership with Chung Shan Medical University. It also verified that Patented peptide sequence (mcIRBP^TM-19) effectively improved blood glucose indicators; the research report will also soon be officially announced.

Carefully selection of patented ingredients with scientific evidence
Many consecutive studies have brought attention to bitter melon peptide, but Hsu Pang-Kuei, PhD states that the extremely precious ingredient from bitter melons used in Patented peptide sequence (mcIRBP^TM-19) requires specific processes and excellent production management to obtain the best results. Analysis by the research team found that many commercially available products that feature bitter melon peptides do not contain this ingredient and are instead bitter melon hydrolysate or extract. These exhibit poor effect and can damage the rights of consumers, which is why it′s important to pay extra attention when shopping.
Hsu Pang-Kuei, PhD reminds diabetics to always follow their doctor′s orders for medication before evaluating whether they require a supplement to improve their blood glucose. The key is to select products with active ingredients that are scientifically proven to receive their full benefit.